【October 31 2016, Hong Kong】On 29 October 2016, Shanghai Fosun Pharmaceutical (Group) Co.,
Ltd. (“Fosun Pharma”, stock code: 600196.SH, 02196.HK) announced in its A-share announcement that Shanghai Henlius Biotech Inc. (“Henlius”), a holding subsidiary under its control, and
AbClon Inc. (“AbClon”) from Korea entered into a license agreement for monoclonal antibody AC101.
AC101, an innovative monoclonal antibody
developed by AbClon targeting gastric cancer and breast cancer, is currently under pre-clinical trial
studies. Under the agreement, Henlius is granted the exclusive rights to
develop and commercialize AC101 across the Great China region. This
cooperation will put into play techniques and advantages of Henlius as an
existing monoclonal antibody development platform of
Fosun Pharma in further diversifying its product lines to enhance its
competitiveness in the anti-tumor therapeutic area.
AC101 is the first novel monoclonal antibody
discovered using AbClon’s proprietary antibody
development platform New Epitope Screening Technology (Nest). Currently there is no similar product in any
market worldwide. According to statistics from Global Data, the gastric cancer treatment
market is projected to reach US$4.4 billion globally
by the year 2024, and the HER2-positive breast cancer
treatment market to reach US$12.7 billion by the year 2023.
At present, AC101 is still under pre-clinical trial studies and it is uncertain that
it will be able to start clinical trials. Any
clinical trial, registration, manufacture and other matters in relation to it
in the relevant region is subject to approval of relevant pharmaceutical
Dr. Scott Liu, President and CEO of Shanghai Henlius indicated that, “Shanghai Henlius’ mission is to provide high-quality,
affordable and accessible healthcare products worldwide. We are very excited to add another promising
antibody product to our expanding portfolio. We believe AC101 in combination with the proprietary recombinant humanized anti-HER2 monoclonal antibody
injection (trastuzumab biosimilar) developed by Henlius will enhance the
efficacy against gastric cancer and breast cancer.” Phase I clinical study for the proprietary recombinant humanized anti-HER2 monoclonal
antibody (trastuzumab biosimilar) developed by Henlius has been completed and the results show that the new drug is safe and has the
same efficacy as the corresponding proprietary drug Herceptin®. Phase III
clinical trial for the new drug will commence within this year.
Dr. Jong-Seo Lee, CEO of AbClon, also
expressed his delight in having a licensing deal with Henlius, one of the most
prominent monoclonal antibody pharmaceutical companies in China, and he looked
forward to more partnerships with premier
biopharmaceutical companies such as Henlius.
Fosun Pharmaceutical (Group) Co.,Ltd.
in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun
Pharma”; stock code: 600196.SH, 02196.HK) is a leading
healthcare Group in the PRC. Fosun Pharma strategically covers important
segments of the healthcare industry value-chain, including pharmaceutical
manufacturing and R&D, healthcare services, medical diagnosis, medical
devices manufacturing and agent, as well as pharmaceutical distribution and
retail, making contribution to improving people’s health. Fosun Pharma
maintains a National Recognized Enterprise Technology Centre and a highly
capable international R&D team, focusing on innovation and research of
therapeutic areas including cardiovascular system, central nervous system,
blood system, metabolism and alimentary system, anti-infection and anti-tumor.
With its commitment to innovation for good health and creating a better future,
Fosun Pharma will continue insisting on the strategic development approach of “organic
growth , external expansion and integrated development”,
striving to be one of the leading enterprises in the global healthcare market.
Henlius Biotech,Inc. is a joint venture company formed by Shanghai Fosun
Pharmaceutical Co., Ltd. and Henlius Biopharmaceuticals Co., Ltd. in
December 2009. The concept of our drug development lies in global
integrative innovation, and we have 3 R&D laboratories located in China
(Shanghai), the US (California) and Taiwan (Taipei). The company focuses on the
development, production and commercialization of mAb biosimilar drugs,
bio-betters and novel mAbs using cutting-edge technology. Products
currently in development cover a variety of therapeutic areas including
oncology and autoimmune diseases. Looking forward,Shanghai Henlius will
continue to pursue technical innovation and operation excellence in drug
discovery and development to improve patients’lives by timely providing them
with quality and affordable protein therapeutics,and strive to be the most
admired biotech company in the world.
Inc., based in Seoul, Korea, is dedicated to research and development of new
antibody therapeutics. The company has developed two platforms: Novel Epitope
Screening Technology (NEST) and novel multi-specific antibody platform, AffiMab
to accelerate the discovery and development of innovative antibody